Evidence map›Paper›PMID 25986446›Full record

ArticleCirculation2015

Xanthine oxidase inhibitors in heart failure: where do we go from here?

Leonardo Tamariz, Joshua M Hare

Abstract readEditorialComment
In one paragraph

Article in Circulation, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Review
  5. Article
  6. Article
  7. Article
  8. Comparative Cardiovascular Risks of Febuxostat and Allopurinol in Patients with Diabetes Mellitus and Chronic Kidney Disease.Medical science monitor : international medical journal of experimental and clinical research · 2024
    Observational
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Antioxidants in Cardiovascular Therapy: Panacea or False Hope?Frontiers in cardiovascular medicine · 2015
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Leonardo TamarizFrom Department of Medicine (L.T., J.M.H.) and Interdisciplinary Stem Cell Institute (J.M.H.), University of Miami Miller School of Medicine, FL; and Veterans Affairs Medical Center, Miami, FL (L.T.).
Joshua M HareFrom Department of Medicine (L.T., J.M.H.) and Interdisciplinary Stem Cell Institute (J.M.H.), University of Miami Miller School of Medicine, FL; and Veterans Affairs Medical Center, Miami, FL (L.T.). jhare@med.miami.edu.

Funding

Cardioprotective Effect of Growth Hormone Releasing HormoneR01HL107110 · NHLBI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI HARE, JOSHUA M · 2011 to 2020
$5.9M
Cell Based Therapy for Non-Ischemic Dilated CardiomyopathyUM1HL113460 · NHLBI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI HARE, JOSHUA M · 2012 to 2018
$4.3M
Cellular Cardiomyoplasty for Chronic Heart FailureR01HL084275 · NHLBI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI HARE, JOSHUA M · 2007 to 2016
$3.8M
Stem Cells for Dilated CardiomyopathyR01HL110737 · NHLBI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI HARE, JOSHUA M · 2011 to 2015
$3.2M
NHLBI NIH HHS R01 HL084275NHLBI NIH HHS R01HL084275NHLBI NIH HHS R01 HL107110NHLBI NIH HHS R01 HL110737NHLBI NIH HHS UM1 HL113460PHS HHS 5UMHL113460
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AllopurinolFemaleHeart FailureHumansHyperuricemiaMaleXanthine OxidaseAllopurinolXanthine Oxidaseantagonists and inhibitorsEditorialsheart failurenitric oxideuric acidxanthine oxidase

Identifiers

PMID25986446
PMCPMC4438774

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.